I-MIBG-based dosimetry yielded a more conservative estimate of maximum allowable activity and would be suitable for planning and limiting organ toxicity with repeat high-dose therapies.
I-MIBG. Organ dosimetry was estimated from the first 131 I-MIBG posttherapy imaging and from subsequent 123 I-MIBG imaging prior to the planned second administration. Three serial whole-body scans were performed per patient 2 to 6 days after 131 I-MIBG therapy (666 MBq/kg or 18 mCi/kg) and approximately 0.5, 24, and 48 hours after the diagnostic 123 I-MIBG dose (370 MBq/kg or 10 mCi/1.73 m 2 ). Organ radiation doses were calculated using OLINDA. 123 I-MIBG scan dosimetry estimations were used to predict doses for the second 131 I-MIBG therapy and compared with 131 I-MIBG posttherapy estimates. Results: Mean ± SD whole-body doses from 131 I-MIBG and 123 I-MIBG scans were 0.162 ± 112 and 0.141 ± 0.068 mGy/MBq, respectively. 123 I-MIBG and 131 I-MIBG organ doses were variable-generally higher for 123 I-MIBG-projected doses than those projected using posttherapy 131 I-MIBG scans. Mean ± SD doses to liver, heart wall, and lungs were 0.487 ± 0.28, 0.225 ± 0.20, and 0.40 ± 0.26, respectively, for 131 I-MIBG and 0.885 ± 0.56, 0.618 ± 0.37, and 0.458 ± 0.56, respectively, for 123 I-MIBG. Mean ratio of 123 I-MIBG to 131 I-MIBG estimated radiation dose was 1.81 ± 1.95 for the liver, 2.75 ± 1.84 for the heart, and 1.13 ± 0.93 for the lungs. No unexpected toxicities were noted based on 123 I-MIBGprojected doses and cumulative dose limits of 30, 20, and 15 Gy to liver, kidneys, and lungs, respectively. Conclusions: For repeat 131 I-MIBG treatment planning, both 131 I-MIBG and 123 I-MIBG imaging yielded variable organ doses. However, 123 I-MIBG-based dosimetry yielded a more conservative estimate of maximum allowable activity and would be suitable for planning and limiting organ toxicity with repeat high-dose therapies.
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-MIBG therapy (MIBG therapy) is increasingly being used in the treatment of patients with chemorefractory or relapsed neuroblastoma (NB), a pediatric malignancy associated with poor prognosis. 123 I-MIBG imaging is a mainstay assessment and the recommended standard imaging modality for NB. [1] [2] [3] [4] The dosing of 131 I-MIBG for therapy in NB has been based on body weight, with regimens ranging from multiple infusions of lowactivity (37-148 MBq/kg or 1-4 mCi/kg) to high-activity MIBG therapy (296-666 MBq/kg or 8-18 mCi/kg); alternatively, some regimens have used fixed doses, and others have based dosing on whole-body dosimetry. 5 Myelosuppression is the most common adverse event and limits the activity that can be administered. However, with the increasing availability of cryopreserved stem cells in patients with NB, high-dose MIBG therapy followed by stem cell rescue to reverse myelosuppression has become the norm for such patients. 6, 7 Other adverse events include transient sialoadenitis, hypertension, and hepatotoxicity.
Response rates, even with high-dose MIBG therapy, are suboptimal; combined therapy with radiation sensitizers has been explored to improve efficacy, 8, 9 and serial high-dose MIBG therapy has been used. 3, 10 High-dose therapies are associated with toxicities, and dose amounts to the normal organ are of concern. Dosimetric estimations are used to allow for maximizing activity administration while keeping normal organ doses within tolerable limits to prevent toxicity. Previous studies have primarily used whole-body radiation and red marrow-absorbed dose estimates. In a study that used pretherapy 123 I-MIBG imaging to predict whole-body dose for MIBG therapy, 11 whole-body counting without imaging showed large intrapatient variations in estimating whole-body-absorbed doses allowing for a maximum 4-Gy total absorbed dose for 2 doses. I-MIBG imaging-derived dose estimates appear to be more reproducible than weight-based dosing; however, it underestimates the therapeutic dose and shows large interpatient variations in tumor-absorbed dose. [13] [14] [15] Furthermore, repeated 131 I-MIBG imaging raises concern about increasing radiation exposure in children. PET-based dosimetry with 124 I-MIBG has been performed and allows for organ and body dose estimations, but it is restricted in terms of broad applicability because of the fact that 124 I-MIBG is currently not US Food and Drug Administration approved 16, 17 or universally available and because radiolabeling requires expertise that limits its use.
While various techniques have been used to assess activity administration, individual organ dosimetry has not been evaluated for planning repeat, tandem MIBG therapy or multiple MIBG infusions. Assessment of organ doses may help individualize therapy and prevent prohibitive radiogenic adverse effects, while allowing for administration of the maximum "safe" therapeutic activities in those who respond to first high-dose therapy. This is especially critical in high-activity or repeat therapies with stem cell support where marrow toxicity is not limiting but organ doses may be therapy limiting; dosimetry will allow for maximizing activity administration while keeping the absorbed dose to individual critical organs such as the lung, liver, and kidney within tolerance limits. 
METHODS

Patients
Patients with high-risk refractory or recurrent NB were treated on a phase II single-arm, open-label study approved by our institutional review board (Clinicaltrials.gov identifier NCT00107289) and in accordance with the Health Insurance Portability and Accountability Act. Informed consent was obtained from all individual participants included in the study. Salient eligibility criteria included age older than 1 year, evidence of evaluable or measurable MIBG-avid disease, and availability of cryopreserved hematopoietic stem cells. Patients with significant renal, cardiac, hepatic, pulmonary, gastrointestinal, and neurologic toxicity were excluded.
MIBG Therapy
All patients were initially treated with a dose of 666 MBq/kg (18 mCi/kg) 131 I-MIBG. Pretreatment saturated solution of potassium iodide and levothyroxine was given for thyroid protection, and a urinary catheter was placed and retained while patients remained in the hospital. Patients were monitored clinically and biochemically for toxicity.
A second dose of therapeutic kg or 18 mCi/kg each) for the liver, kidneys, and lung were less than 30, 20, and 15 Gy, respectively. 19 The estimation of absorbed doses was based on actual calculations of absorbed doses from the first 131 I-MIBG posttherapy scans and projections from dosimetry calculations from serial 123 I-MIBG scans performed at follow-up after the first therapy dose. If the estimated absorbed doses to target organs (based on both the actual and projected) were below tolerance doses, the second therapy dose was administered at 666 MBq/kg or 18 mCi/kg (Fig. 1) . Alternately, the administered dose was reduced based on the projected permissible activity.
Post-MIBG Therapy
After completing protocol requirements, patients could receive autologous stem cell rescue to reverse myelosuppression as clinically needed. Patients were followed for toxicities until hematopoietic recovery (absolute neutrophil count >500/μL and transfusionindependent platelet count >20,000/μL) was observed.
Pharmacokinetics
Pharmacokinetic studies after 131 I-MIBG therapy included (a) whole-body counting using an ionization-chamber survey meter (Keithley Model 36100; Keithley Instruments, Inc, Cleveland, Ohio) calibrated with 137 Cs; (b) blood clearance by radioassay of serial blood samples; and (c) whole-body and organ activity measured by conjugate-view whole-body gamma-camera scanning. Blood activity concentrations and gamma-camera imaging-derived wholebody and organ activities were used for dosimetry. We compared the whole-body cumulated activities derived from whole-body counting, gamma-camera imaging, and combining the counting and imaging data in order to assess the differences in the wholebody cumulated activity derived by these 3 different approaches.
Whole-Body Counting
Exposure rate measurements (at surface and at a 1-m distance from the patient) were recorded immediately postinfusion (time 0) and at least once daily while the patient remained in isolation following the 131 I-MIBG therapy. Measurements were normalized to the time 0 measurement to yield the corresponding whole-body retention fraction FIGURE 1. Study schema.
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I. Whole-body retention fractions were fit to a biexponential function (in some cases, a monoexponential function).
Blood Sampling and Dosimetry
Blood samples were drawn at time 0 and then at 2,~4,~8, 16,~24,~48,~72,~96, and~168 hours after the first MIBG therapy only. Measured aliquots of blood were assayed in duplicate in a scintillation well counter (LKB Wallach, Inc, Turku, Finland) calibrated for 131 I, and the net count rates converted to activity concentrations in percentage of the injected activity per gram (% ID/g). The resulting time-activity concentration data decay corrected to the time of administration were fit to a biexponential function. The fitted biological clearance constants were converted to effective clearance constants by incorporation of the 131 I physical decay constant and the blood 131 I cumulated activity concentration calculated by analytic integration of the resulting function. The mean bloodabsorbed dose was calculated by multiplying the blood cumulated activity concentration by the 131 I equilibrium dose constant for nonpenetrating radiation (ie, beta particles), assuming complete absorption of the 131 I beta particles in blood and ignoring the much smaller 131 I gamma-ray absorbed-dose contribution.
Imaging
A Skylight dual-head gamma-camera system (Philips Inc, Bothell, Wash) was used for all whole-body conjugate (anterior and posterior)-view scanning with high-energy collimators for 131 I imaging (photopeak energy window: 364 keV ± 10%) and medium-energy collimators for 123 I imaging (159 keV ± 10%). A calibrated standard of~250 μCi of either 131 I or 123 I was included in the field of view for each scan and used to convert the net geometric-mean counts to activity (in μCi) and then % administered activity. Three serial conjugate-view whole-body gamma-camera scans were acquired from 48 to 120 hours after 131 I-MIBG infusion such that sequential scans were performed at least 1 day apart ( Fig. 2A) . Five to seven weeks later, patients were injected with ) and underwent conjugate whole-body imaging on the day of injection (2-4 hours) and at approximately 24 and 48 hours after infusion (Fig. 2B ).
Whole-Body and Organ Dosimetry
Regions of interest (ROIs) were manually drawn around the whole body, heart, liver, and lung on the whole-body scans and on the reference standard imaged with the whole-body scans. Region of interest analyses were performed using a Hermes imaging system (Hermes Medical Solutions, Chicago, Ill). Regions of interest were copied and pasted to all other image sets using software that allowed visualization and linking of multiple image sets. For the whole-body and foregoing normal-organ ROIs, the geometric-mean net count rates were converted to activities (in kBq) using the standardderived system calibration factor (in cpm/kBq). The resulting non-decay-corrected time-activity data for each organ were fit to biexponential functions, which were then integrated to yield the I-MIBG time-activity data were calculated using the OLINDA dosimetry program. 20 Whole-body and organ masses for the anatomic model in OLINDA whose whole-body mass most closely matched that of the patient were scaled in proportion to the patient-to-anatomic model whole-body mass ratio.
Statistical Analyses
The data for 131 I-MIBG dosimetry and 123 I-MIBG dosimetry were summarized using the median and median absolute deviation (MAD), a nonparametric alternative to standard deviation. The Wilcoxon signed rank test for paired data was used to test for a significant difference in doses estimated between I-MIBG methods. The whole-body and blood clearance data were correlated using the Spearman rank correlation. I-MIBG dosimetry projections that showed larger than 30-Gy cumulative dose to liver if the second dose was also 666 MBq/kg (18 mCi/kg). The activity for the second administration was reduced by 39% and 58% (from the proposed 18 mCi/kg) 131 I-MIBG dose for these 2 patients to keep the total absorbed dose to liver at less than 30 Gy.
RESULTS
Patients and Therapy
Fourteen of the total 33 patients did not receive a second treatment because of progressive disease or lack of response (n = 12), prolonged severe myelosuppression (n = 1), or sepsis (n = 1) after the first dose.
Toxicities
All patients experienced expected thrombocytopenia of grade 3 or greater after either single or dual tandem MIBG therapy (Table 1) , and neutropenia grade 3 or greater was experienced by 27 and 17 patients in the single or tandem MIBG therapy groups, respectively. Median ± SD post-stem cell rescue times to recovery to absolute neutrophil count of greater than 500/μL was 13 ± 4.6 days for single versus 13 ± 2.7 days for double MIBG therapy. Median time to transfusion-independent platelet recovery for single versus double MIBG therapy was 24 ± 4 versus 23 ± 4.9 days (P > 0.1 for both by Student t test). Three patients developed neutropenic sepsis, 2 patients after the first MIBG therapy and 1 patient after the second. There was no statistical difference in the incidence of toxicities after 1 or 2 doses of MIBG therapy (P > 0.1 for vomiting and hematopoietic toxicities). Nonhematopoietic toxicities were rare in both single and double MIBG therapy groups. No major organ toxicities were present in any patient, with a median followup of 3.3 years (range, 2-6.8 years) in 10 surviving patients or until the time of last follow-up in those who died of disease. Five patients who received 2 doses survived (median follow-up of 2.5 years; range, 2.1-3.6 years) after the second dose, and no organ dysfunction was noted. Following single dose administration, thyroid function tests performed at 3 to 6 months after administration showed grade 1 toxicity in 2 (18.2%) of 11 patients, whereas for those who received 2 doses, 16 of 19 patients had thyroid function Clinical Nuclear Medicine • Volume 42, Number 10, October 2017 MIBG Therapy: Prospective Organ Dose Estimate tests within the 3-to 6-month follow-up, of which 2 (12.5%) of 16 patients had grade 1 toxicity. None of the patients required thyroid hormone supplementation at any time point up to the last follow-up.
Whole-Body Clearance and Dosimetry
The clearance of activity from the body generally followed a biexponential function, with most (~90%) of the activity cleared with a rapid initial phase and the remainder of the activity clearing more slowly (Figs. 3A, B) . Whole-body data for 
Blood Clearance
Blood time-activity data were collected only for the first 131 I-MIBG therapy administration and followed a biexponential function in all cases (n = 31). Approximately 80% of blood activity was cleared very rapidly, with a mean half-time of 1.3 ± 0.80 hours I-MIBG posttherapy scans: anterior and posterior whole-body images performed at 48 hours (A), 72 hours (B), and 120 hours (C) after injection. A reference standard was included for imaging at all time points (arrows). Images show physiologic uptake in the liver, spleen, gastrointestinal tract, kidneys, and bladder. Uptake is also seen in the left pelvic lesion (arrowhead). 123 I-MIBG scans: anterior and posterior whole-body images performed at 1.5 hours (D), 24 hours (E), and 48 hours (F) after injection. A reference standard was included for imaging at all time points (arrows). Physiologic uptake is seen in the heart, liver, spleen, gastrointestinal tract, and bladder.
(range, 0.22-3.47 hours), with the remainder of the blood activity cleared more slowly, with a mean half-time of 31.7 ± 35.9 hours (range, 14.4-216 hours) (Fig. 3C ).
Organ Dosimetry
Estimates of absorbed doses are provided in Table 2 . Notable organ-absorbed doses (mean ± SD) in mGy/MBq (rad/mCi) calculated from the first I-MIBG posttherapy scan estimates (P = 0.21 and 0.12, respectively). Collectively for adrenals, brain, kidneys, muscle, pancreas, red marrow, osteogenic cells, skin, spleen, thymus, and thyroid, radiation doses tended to be greater for the 131 I-MIBG therapy than for the 123 I-MIBG scan estimates. The dose estimates for these organs were derived from OLINDA projections.
The interpatient variability in estimated radiation doses was significantly greater with 123 I-MIBG as compared with 131 I-MIBG for both the heart wall (MAD, 1.50 vs 0.58; P = 0.005) and the liver (MAD, 1.48 vs 1.20; P = 0.006), whereas for total body the variability was significantly greater for 
DISCUSSION
Although
131
I-MIBG therapy has been used for a number of years for treatment of neuroendocrine tumors and NB, response rates for currently used activities remain suboptimal. In NB, metastasis to bone marrow occurs in most patients, and hematopoietic stem cells harvesting and banking are increasingly being done in anticipation of infusing them to reverse the myelosuppression that may be associated with high-dose chemotherapy regimens and also high-dose MIBG therapy. 21 Thus, as opposed to myelosuppression, toxicity to nonhematopoietic organs is now dose limiting. Dosimetry studies to date have primarily used only wholebody and red marrow-absorbed dose estimates to plan 131 I-MIBG therapy administrations, generally considering blood doses as limiting. Monsieurs et al 11 showed the feasibility of using pretherapy 123 I-MIBG imaging for predicting whole-body doses for 131 I-MIBG, but only whole-body dosimetry was calculated as opposed to individual organ dosimetry, and only 2 imaging time points up to 24 hours after injection were used for 123 I-MIBG estimations. Other methods such as whole-body counting with survey meter 22 or use of whole-body retained activity to estimate maximum 4 Gy total absorbed dose for 2 131 I-MIBG therapy administrations 12 have also shown large variations (Fig. 4) .
Assessment of individual organ doses, as opposed to previously used whole-body-absorbed doses only, would help individualize therapy; in particular, repeat treatments with high-dose 131 I-MIBG would allow for maximizing activity administration while keeping absorbed doses to individual critical organs such as lung, liver, and kidney within tolerance limits. As stem cell support for marrow toxicity is available, organ toxicity rather than marrow toxicity is of higher concern in these patients. We therefore evaluated I-MIBG imaging for organ and whole-body radiation dose estimation for planning the dose for the second 131 I-MIBG therapy. Our study shows that, using 123 I-MIBG imaging, organ dosimetry is practical and allows for treatment planning to prevent major adverse effects to normal organs. There was no significant additional or incremental nonhematologic (organ) toxicity in patients who received second therapy based on our dosimetric estimates. In 2 cases, the organ doses were over the maximum allowed radiation limits with 2 full high-dose administrations (666 MBq/kg or 18 mCi/kg) of the 131 I-MIBG therapy. In those 2 cases, the activity for the second treatment was reduced based on estimations with 123 I-MIBG imaging. In both cases, the limiting organ was liver and required 39% and 58% lower administered activities from the preplanned dose (666 MBq/kg or 18 mCi/kg) for the second 131 I-MIBG administration. Follow-up in these patients after 2 therapies showed no signs of liver dysfunction up to the last follow-up, to a median follow-up of 2.5 years. Marrow toxicity, as expected, was seen in a majority of the patients with this treatment, consistent with the general experience with high-dose 131 I-MIBG therapy. However, no significant difference was evident in the marrow toxicity profile for those who received only a single dose versus those who received a second 131 I-MIBG therapy. The radiation doses estimated by 123 I-MIBG versus 131 I-MIBG posttherapy scanning showed significant differences, with the radiationabsorbed doses to the liver, lungs, and heart generally greater with 1-2.7) . For other organ systems including marrow and whole body, however, dose estimates were generally lower for 123 I-MIBG, with an average ratio of 0.78 (0.65-0.97). There was a large variation in the individual organ dosimetry estimates for both methods, which is expected because of individual differences likely related to biological clearance. Technical and practical limitations that influence accurate estimations may contribute to these differences. Liver and heart wall RAD estimates were significantly greater for 123 I-MIBG compared with 131 I-MIBG estimates (P < 0.001 for both the liver and heart wall). Although the exact reason for this is not entirely clear, it may be related to technical aspects. In 5 of the 8 cases with higher cardiac uptake on the 123 I-MIBG, there was disease in the mediastinum and prominent uptake in the liver that could have contributed to the estimations from the ROI placements. It is likely that higher visibility of lesions on posttherapy scans allows for placement of ROI away from the lesion site. This, however, does not entirely explain the discrepancy in other cases. In addition, the fact that dose estimates were variable and generally higher for key major organs than those derived from the first I-MIBG and would be a suitable method for planning and limiting organ toxicity with repeat high-dose therapies.
